REGENXBIO Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 26/100
What the filing says
REGENXBIO priced an underwritten public offering of 10,003,889 common shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant, with gross proceeds ~$100 million before expenses. Underwriters (Morgan Stanley, J.P. Morgan, Leerink, Mizuho) received a 30-day overallotment option for 1,667,250 additional shares. Closing scheduled July 20, 2026.
Why this rating
Capital raise of ~$100M is ~26% of company's $385M market cap—meaningful for cash but routine equity financing. No strategic M&A, operational change, or loss event. Standard dilutive offering.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.